Literature DB >> 7695320

Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily.

C Santré1, H Georges, J M Jacquier, O Leroy, C Beuscart, D Buguin, G Beaucaire.   

Abstract

In this study, concentrations of amikacin in blood and bronchial secretions of 10 patients with mechanical ventilation for acute respiratory failure due to pneumonia were measured. One-half of the patients received amikacin twice daily, and the others received once-daily administration. Concentrations in bronchial secretions of the patients treated twice daily ranged from 3 to 4 mg/liter, i.e., they were similar to those in previously published reports. Peak concentrations in bronchial secretions occurred between 3 and 4 h after the onset of infusion, and they reached 4.8 +/- 2.6 mg/liter on day 1 and 4.0 +/- 2.7 mg/liter on day 3. For the patients treated with amikacin once daily, concentrations in bronchial secretions were more than twofold higher, above 8 mg/liter for 12 h. Peak concentrations in bronchial secretions occurred between 3 and 4 h after the onset of infusion and reached 13.6 +/- 9.3 mg/liter on day 1 and 10.4 +/- 3.5 mg/liter on day 3. These concentrations are higher than the MICs for less sensitive bacterial strains, such as Acinetobacter spp. and Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695320      PMCID: PMC162523          DOI: 10.1128/AAC.39.1.264

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity.

Authors:  R Garraffo; H B Drugeon; P Dellamonica; E Bernard; P Lapalus
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 2.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections.

Authors:  G Beaucaire; O Leroy; C Beuscart; P Karp; C Chidiac; M Caillaux
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

4.  A study of amikacin given once versus twice daily in serious infections.

Authors:  R Maller; B Isaksson; L Nilsson; L Sörén
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790

5.  [Pharmacokinetics of amikacin in bronchial secretions].

Authors:  P Even; E Bergogne-Berezin; P Reynaud; G Berthelot
Journal:  Nouv Presse Med       Date:  1979-10-31

Review 6.  Does serum protein binding inhibit tissue penetration of antibiotics?

Authors:  T Bergan; A Engeset; W Olszewski
Journal:  Rev Infect Dis       Date:  1987 Jul-Aug

Review 7.  Penetration of antibiotics into respiratory secretions.

Authors:  J E Pennington
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

8.  Bronchial secretion levels of amikacin.

Authors:  W L Dull; M R Alexander; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

9.  Endotracheally administered antibiotics for gram-negative bronchopneumonia.

Authors:  J Klastersky; F Carpentier-Meunier; L Kahan-Coppens; J P Thys
Journal:  Chest       Date:  1979-05       Impact factor: 9.410

Review 10.  Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria.

Authors:  J Klastersky; J P Thys; G Mombelli
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb
View more
  12 in total

1.  BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia.

Authors:  Michael S Niederman; Jean Chastre; Kevin Corkery; James B Fink; Charles-Edouard Luyt; Miguel Sánchez García
Journal:  Intensive Care Med       Date:  2011-12-07       Impact factor: 17.440

Review 2.  Clinical pharmacokinetics and pharmacodynamics of isepamicin.

Authors:  M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

3.  Quantification of amikacin in bronchial epithelial lining fluid in neonates.

Authors:  C Tayman; M N El-Attug; E Adams; A Van Schepdael; A Debeer; K Allegaert; A Smits
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 4.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 5.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

6.  Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Carleton M Sherman; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

8.  Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa.

Authors:  Spyros D Mentzelopoulos; Maria Pratikaki; Evangelia Platsouka; Helen Kraniotaki; Dimitris Zervakis; Antonia Koutsoukou; Serafim Nanas; Olga Paniara; Charis Roussos; Evangelos Giamarellos-Bourboulis; Christina Routsi; Spyros G Zakynthinos
Journal:  Intensive Care Med       Date:  2007-06-05       Impact factor: 17.440

9.  Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.

Authors:  Shashikant Srivastava; Chawanga Modongo; Chandima W Siyambalapitiyage Dona; Jotam G Pasipanodya; Devyani Deshpande; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 10.  Aerosol delivery during invasive mechanical ventilation: a systematic review.

Authors:  Jonathan Dugernier; Stephan Ehrmann; Thierry Sottiaux; Jean Roeseler; Xavier Wittebole; Thierry Dugernier; François Jamar; Pierre-François Laterre; Gregory Reychler
Journal:  Crit Care       Date:  2017-10-21       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.